‘Basaglar,’ price-competitive biosimilar, launched in Korea

Published: 2017-04-17 16:29:00
Updated: 2017-04-17 13:36:01

‘Basaglar,’ the first insulin glargine biosimilar in Korea, will be launched.

Lilly Korea and Boehringer Ingelheim Korea held a meeting to celebrate the launch of ‘Basaglar(generic name: insulin glargine 100U/ml),’ a insulin glargine biosimilar, on the 13th and revealed the Korean diabetes patie...


- Email service daily and homepage access.
  1. $300 per month. ($3,240 per year)
  2. 5 Email holders per each company.
  3. Anual contract base.

Original Korean

Address: 295-1, Chungpa-Ro, Yongsan-Gu, Korea
Phone: 02-3270-0114 | Fax: 02-3270-0129 | Email: eyd@yakup.com

Copyright © Yakup Shinmoon, Inc. All Rights Reserved.